FDA 483 - Sandoz GmbH - September 10, 2018

Sandoz GmbH, an API and drug manufacturer in Kundl, Austria, was cited for significant deficiencies in its quality control systems. Observations included inadequate investigations into sterility failures, insufficient laboratory controls for critical surface monitoring, and a lack of validated sterilization processes. Additionally, the firm lacked written procedures for equipment cleaning and maintenance.